ROCE Insights For AcelRx Pharmaceuticals

By Benzinga4 days ago

AD

During Q3, AcelRx Pharmaceuticals's (NASDAQ:ACRX) reported sales totaled $1.37 million. Despite a 32.24% in earnings, the company posted a loss of $9.04 million. AcelRx Pharmaceuticals collected $2.92 million in revenue during Q2, but reported earnings showed a $6.83 million loss.

Why ROCE Is Significant

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally ...

Full story available on Benzinga.com

Continue read on benzinga.com